While clearly different in their aims and means, classification and diagnosis both try to accurately label the disease patients are suffering from. For systemic lupus erythematosus (SLE), this is complicated by the multi-organ nature of the disease and by our incomplete understanding of its pathophysiology. Hallmarks of SLE are the presence of antinuclear antibodies (ANA), and multiple immune-mediated organ symptoms that are largely independent. In an attempt to overcome limitations of the current sets of SLE classification criteria, a new fourphase approach is being developed, which is jointly supported by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). This review attempts to delineate the performance of the current sets of criteria, the reasons for the decision for classification, and not diagnostic, criteria, and to provide a background of the current approach taken. Lupus (2016) 25, 805-811.
Introduction
Defining systemic lupus erythematosus (SLE), both in classification and in clinical diagnosis, has remained one of the challenging questions in Rheumatology. After all, the very nature of this condition is not fully understood. SLE will often be the underlying condition when patients present with either a combination of fever, lymphadenopathy, malar rash and polyserositis, or with immune complex glomerulonephritis, but may also present as new-onset polyarthritis or another organ-specific manifestation with no other obvious symptoms. Therefore, some experts view SLE as a syndrome rather than a single disease. Dividing SLE into separate entities in such a way, however, might mean assigning specific phenotypes to very small groups of patients, or even to single patients. Abolishing the common idea of one disease would help neither our understanding of the pathophysiology of the disease, nor clinical decision making today. In our view, there are sufficient similarities to keep the faces of SLE together, and we favor the standpoint of seeing SLE as one disease.
It is of course evident that SLE can have literally hundreds of manifestations related to autoimmunity, which possibly are independent of each other. In addition to cellular immune activation, it is the hallmark of the disease that these manifestations are due to various antibodies and often to immune complexes consisting of autoantigen and autoantibodies. In fact, essentially all inflammatory manifestations of SLE are associated with immune complexes, while cytopenias and some nervous system symptoms are probably initiated by the direct effects of autoantibody binding. 1, 2 For many organ manifestations, the autoantibody specificities at fault are not fully known. However, in the worldwide routine setting, there are still more than a dozen autoantibodies 3 that are being measured and are associated with SLE at different degrees of sensitivity and specificity ( Table 1) .
Most of the autoantibodies measured in clinical practice for SLE assessment are directed against nuclear antigens. The complete absence of antinuclear antibodies (ANA) is, in fact, a rather uncommon situation in patients whom most SLE experts would find to have SLE, [4] [5] [6] and roughly half of all SLE patients have antibodies to double-stranded DNA (dsDNA), at least in episodes of disease activity. 7 Antibodies to dsDNA, but also those to RNA, achieve binding to the nuclear acids via differences in charge. This important biophysical characteristic, presumably in an indirect way via histone binding, 8 also explains their affinity to basal membranes. It appears somewhat uncertain whether the propensity to form such antibodies truly is an inherent feature of the disease, or whether the immune system is simply more prone to developing such antibodies based on the MHC association than autoantibodies to other antigens.
Even more than the propensity to develop ANA, the development of multiple autoantibodies is the cardinal feature of SLE. 9, 10 In fact, it appears that the development of SLE is associated not only with the new occurrence of autoantibodies typical of SLE, but also with the development of antibodies associated with organ-specific autoimmunity, such as autoimmune thyroiditis. 9, 10 The distinction between organ-specific and systemic autoimmunity is still underexplored and imprecise. Since we commonly limit testing to well-defined autoantibodies, the known antibody findings only constitute a part of the whole picture. Many other autoantibodies may be present. It is still unclear whether there are common or numerous distinct mechanisms that underlie this dangerous main feature of the disease.
SLE classification-the ACR and the SLICC criteria
To a significant degree, both the 1982 (and revised 1997) American College of Rheumatology (ACR) and the 2012 Systemic Lupus International Cooperating Clinics (SLICC) sets of classification criteria depict the above-sketched picture of the prototypical multi-organ systemic autoimmune disease. 4, 5, 11 These criteria mostly list organ manifestations that are likely antibody and/or immune complex mediated in this setting.
Being among the first sets of criteria derived with modern technology, the 1982 (and revised 1997) ACR criteria have shaped the concept of SLE of most of the physicians practicing today. In fact, most physicians will have learned them by heart. This very fact, however, also represents a point of criticism. One of the reasons for learning the criteria by heart was that they are not entirely intuitive. Nevertheless, they have worked well for clinical and various other studies, and have often even been (inadequately) used for diagnostic purposes.
Over time, new features of SLE have been described, such as subacute cutaneous LE, and it has been debated whether all of the cutaneous and mucocutaneous features-such as UV sensitivity, oral ulcers and skin lesions-are indeed independent, or represent manifestations of the same SLE manifestation. 12 While specificity was usually considered satisfactory, the sensitivity of the ACR criteria has been seen as suboptimal, in new-onset and childhood SLE in particular. 13 Moreover, the 1997 revision was never formally tested. The latter has changed through a substantial effort by the SLICC group to devise new SLE criteria. In this process the SLICC investigators also validated the 1997 criteria, and found a sensitivity of 83% and a specificity of 96%. 5 The SLICC group have made a number of a priori choices that have shaped their set of criteria. Primarily, they decided that the structure of the criteria should stay the same. In consequence, four features are still needed for SLE classification, and the features have not been weighted. However, there is one important exception: biopsy-proven lupus nephritis was declared to sufficiently classify the disease when in combination with ANA or anti-dsDNA antibodies. The SLICC investigators also chose to better depict the role of autoimmunity. This resulted in the definition that classification demands at least one immunological and at least one clinical criterion being fulfilled. While both the decisions on biopsy-proven lupus nephritis and on the necessity to have at least one immunological criterion make intuitive sense, it is a fact that these were more eminence based than data driven. The other choice that was not entirely based on data is the inclusion of a full textbook list of all possible forms of acute, subacute, and chronic cutaneous LE, which were subsequently tested together under these combined headings. Accordingly, there are no data on the performance of rather unusual entities such as lupus tumidus, which is also rarely associated with SLE. [14] [15] [16] Similarly, the list of neuropsychiatric symptoms was expanded, and some of the other definitions were slightly modified.
The SLICC group defined improved sensitivity as a major goal, and their SLE criteria have indeed clearly surpassed the 1997 ACR criteria in this regard. Several groups have compared the two sets, and there is complete agreement that the SLICC criteria are more sensitive. 13, [17] [18] [19] [20] The SLICC criteria sensitivity has been found in the range between 92% and 97%, whereas the 1997 ACR criteria had 77% to 91% sensitivity. However, and not entirely unexpectedly given the similar structure, specificity dropped from 91-96% for the 1997 ACR criteria to 74-88% for the SLICC criteria. It is therefore not clear which set of criteria is more useful, and there is some resulting uncertainty and local difference in the preferred set. Having only one set would, in the longer term, be clearly preferable, but for trial purposes either of the two is acceptable to the Food and Drug Administration and European Medicines Agency regulatory agencies.
Differences between diagnosis and classification
As compared with classification by criteria, clinical diagnosis is actually quite different. Diagnosis and classification both aim at accurately deciding whether the underlying disease in an individual patient is or is not SLE. However, the purposes differ, and so do the means ( Table 2) . 21 While classification mainly defines a rather homogenous set of patients for research purposes, diagnosis focuses on the individual patient's prognosis and therapy. In consequence, suboptimal sensitivity in diagnosis can be a very serious problem. With 95% sensitivity, 1 in 20 true SLE patients would still be missed and not given appropriate treatment. This is one of the most relevant arguments against diagnostic criteria. Not meeting the diagnostic criteria would endanger these patients, if in need of expensive therapies in particular. This is one of the major arguments why neither ACR nor EULAR are willing to back diagnostic criteria. 21 Low specificity may also have an impact on health care cost, in part caused by additional testing. 22 However, the diagnosis of SLE in itself, without any proof of relevant organ disease, should therapeutically lead to the use of hydroxychloroquine (and perhaps vitamin D) only. Basing more therapeutic steps on the SLE diagnosis would be a significant misconception.
On the other hand, criteria will only be useful if practicable. Optimally, they are easily learned by heart, or printed on one single page. In contrast, in making a diagnosis the conventional way, the treating physician will be able to take any piece of information into account. A family history of autoimmunity, or rather unspecific features such as arthralgias, myalgias, or fatigue, may tip the balance towards the diagnosis. Additional information, such as old laboratory reports that showed leukocytopenia long before disease onset, may lead to discounting certain features. It is important in this regard that diagnosis is seen as an ongoing and reiterative process. Physicians should re-question their diagnosis whenever the course of disease does not fit expectations.
The latter would have dramatic consequences in classification. A patient fulfilling classification criteria for SLE, who would accordingly be included into a randomized therapeutic trial, cannot be simply withdrawn by post hoc change of classification. Specificity thus is a critical issue in classification. In contrast, for classification purposes, 90% sensitivity would allow for inclusion of most patients, and the 10% missed will usually not make a dramatic difference. Therefore, fundamentally different from diagnosis, sensitivity is not so Table 2 Differences between diagnosis and classification.
Diagnosis Classification
Aim Individual prognosis and therapy.
Homogenous groups for research purposes.
Information base
Theoretically unlimited information of various natures and sources.
Feasible, and therefore limited set of objective criteria only. Sensitivity Critical issue (will often limit access to therapy).
Low sensitivity narrows patient population, but is usually not critical. Specificity
Diagnosis will be questioned if new information sheds doubt.
Critical issue (starting point classification cannot be corrected).
critical in classification. These differences are also shown in Table 2 .
SLE diagnosis
It is, therefore, evident why neither the ACR nor the SLICC classification criteria for SLE should be directly used for diagnostic purposes. Even the best sensitivity and specificity values of these sets show that at least 4% of patients would incorrectly be given, or not given, the diagnosis. Nevertheless, these criteria shape our understanding of SLE. They provide a framework to model our diagnostic process on; this process will eventually go much further. What is it, then, that will indicate a diagnosis of SLE? Looking at the two sets of criteria, they mainly depict multiple autoimmune features that together form the disease. Some of these features are quite specific, such as immune complex glomerulonephritis or autoantibodies to the Smith (Sm) antigen. 4, 5 Others may be relatively specific given the right test and/or the right circumstances, such as anti-dsDNA antibodies or pleuritis in the absence of infection and pulmonary embolism. Still others, including positive ANA or arthritis, are in fact quite unspecific. 5, 23 Under these circumstances, differential diagnoses are an important aspect of the diagnostic work-up. These include infections (viral infections, in particular), hematological disease, and a wide variety of autoimmune diseases. The latter include entities clearly distinct from SLE, such as Hashimoto's thyroiditis, rheumatoid arthritis or primary Sjo¨gren's syndrome, but also such that can occur both as entities on their own or as part of the SLE spectrum, for example anti-phospholipid syndrome, autoimmune hemolytic anemia, or cutaneous LE.
The challenge is to screen the patient's symptoms and results for those SLE-compatible symptoms most probably induced by immune complexes, or by specific autoantibodies (IgG type). Complement consumption, usually measured as decreased C3c and/or C4, is evidence for immune complex disease. Two or more independent antibody-mediated or immune complex-mediated features that are compatible with SLE will usually make the diagnosis likely. However, there are situations that make a firm diagnosis difficult. A prominent example is bacterial endocarditis, which often leads to immune complex disease, 24 and may be accompanied by various immune phenomena.
If there is clinical suspicion of SLE, ANA usually is a good screening test with high sensitivity.
Nevertheless, if there is substantial evidence for the disease, testing for anti-dsDNA antibodies and antibodies to extractable nuclear antigens (ENA) is recommended in addition. 25, 26 This is mainly based on findings that anti-Ro60 and certain other SLE-related autoantibodies may be missed by ANA testing using HEp-2 cells. 27 In our opinion, ANA (or ENA or anti-dsDNA antibodies) plus at least two independent SLE organ symptoms not otherwise explained, or one such symptom and an independent antibody, usually make the diagnosis quite likely. For example, arthritis in the absence of anti-CCP antibodies, but with positive ANA and positive anti-dsDNA antibodies (detected by a specific test) will be diagnosed as SLE, unless there is an acute infection known to often elicit autoantibodies. It is interesting that a similar approach was independently used in Sweden. 19 It is obvious that more specific symptoms will be given more weight in the diagnostic process. Anti-dsDNA antibodies in the absence of ANA should be regarded with great caution, since this situation means that one result must be clinically wrong. Nevertheless, and without any fault on the part of the laboratory, such situations occasionally occur.
In most instances, this is a fairly straightforward approach, but it may, for example, be challenging to decide between infection plus SLE and infection alone. There are two important caveats. In our opinion, nobody should receive a diagnosis of SLE if there are no disease symptoms. Autoantibody combinations may eventually be found to predict future disease, 28, 29 and this might then invite early therapeutic measures in the future, but there is no disease without symptoms. The other aspect is that a diagnosis of SLE in itself calls for hydroxychloroquine, and probably vitamin D and sun protection, but neither necessitates glucocorticoids or immunosuppressive agents, nor does it impact on who best cares for an individual patient. In the latter regard, two different, independent LE skin manifestations in the presence of ANA will usually mean underlying SLE, but the patient will still be best cared for by a dermatologist.
A process towards new classification criteria
In full awareness of the differences between diagnosis and classification of SLE, 21 would it not still be helpful to get closer to the diagnostic process with classification criteria? A feasible set of classification criteria will still not make for a diagnostic tool, but parallel ways of reasoning for classification and diagnosis would make life easier. Therefore, we have embarked on a large SLE criteria project, which is jointly supported by the EULAR and the ACR, and accordingly guided by a steering committee of 12 members. The aim is to develop classification criteria with specificity comparable with the ACR 1997 criteria, but with improved sensitivity, in early disease in particular. 30 In addition, we would like to arrive at a more intuitive approach that is easier to learn. It is important that the criteria approach rigorously keeps to scientific methods, and that circular reasoning is avoided. [31] [32] [33] [34] In order to achieve this, a four-phase process was developed. In phase I, publications on ANA sensitivity and specificity were collected in a systematic literature review. 6, 35 This was based on the idea that in a patient with clinical suspicion of SLE, such as in a young female patient with otherwise unexplained myalgias and fatigue, the next step in diagnosis would be to test for ANA. Likewise, for classification criteria, the performance characteristics of ANA would better fit the description of an entry criterion. HEp2 ANA immunofluorescence data of 10,089 SLE patients was included, and analyzed by meta-regression. At a titer of 1:80, a sensitivity of 98.1% was calculated, with a corresponding specificity of 83.3%. At 1:160, sensitivity was 95.4%. Accordingly, ANA of at least 1:80 may indeed represent a useful entry criterion. Additional tests, for example for antibodies against DSF-70, which almost exclude SLE, could improve ANA specificity, 36 but they are not (yet) available worldwide. In the remainder of the first phase, the focus has been item generation, based on three different approaches. First, a large international expert Delphi exercise resulted in a list and rating of criteria that should be considered for SLE classification for adults as well as for children. 37 Second, in an international, multiethnic, adult early SLE patient cohort, findings in patients with SLE were compared with those of patients with mimicking conditions. 38, 39 Third, patient members of the German lupus patient association were approached via their quarterly magazine ''Schmetterling'' (butterfly), and asked to anonymously fill in and mail a paper survey on symptoms they had around the onset of their disease. More than 300 patients responded. 40 The inclusion of the patient perspective has not historically been done in criteria development, and is a novel aspect of this work.
In the second phase, item reduction was done in a nominal group technique exercise with the steering committee and a group of high-profile SLE experts from both North America and Europe who were not members of the steering committee. The expert panel distinguished potential ''entry criteria'', which would be required for classification, from other potential ''additive criteria.'' Redundant or poorly performing criteria were removed. An abstract reporting the results has been submitted to the 2016 EULAR congress in London. Since there has been a suggestion that criteria cluster into clinically sensible domains or ''buckets'', it is currently being evaluated whether single features are independent of each other. This is done both in a literature review and using the data of the early patient international cohort. With this information, the items will be weighted in Phase 3, using multicriteria decision analysis, 41, 42 as was done for the ACR/EULAR rheumatoid arthritis and systemic sclerosis classification criteria. [43] [44] [45] [46] Finally, in Phase 4, the newly derived candidate criteria will be tested in large independent patient cohorts, and against both the 1997 ACR and the 2012 SLICC criteria.
Conclusions
In part because the medicolegal implications of not meeting diagnostic criteria for SLE in an SLE patient would convey risks, there is consensus that diagnostic criteria will not be backed by either EULAR or ACR. In contrast, classification criteria not only shape our understanding of the disease, but also serve as a useful backbone for the diagnostic approach in an individual patient. Thus, further improving the classification criteria appears worthwhile. The challenge to classify a highly variable disease such as SLE, which is characterized by a tendency to develop multiple autoantibodies, has not changed since the 1982 ACR criteria. While some clinical advances, including the definition of additional forms of cutaneous lupus and several newly described autoantibodies, have enriched the field, most of the more common features were known already in 1982. Given the high quality of the available sets of criteria, which slightly differ in sensitivity and specificity, devising new classification criteria for SLE is a considerable challenge. In a large, collaborative transatlantic project, we hope to meet this challenge. At least, in a scientifically rigorous approach, a robust set of criteria should be formed and validated, all of which will be based on a strong rationale. The project is intended to be fully inclusive, and everybody who wants to take part is invited to contact all or any of the authors. Hopefully, 2017 will bring us back to uniformly accepted criteria.
